PC. Luis Quiroz Ravines
In the world millions of people suffer from a condition called "alopecia areata" characterized by localized loss of hair. One of its features is its round shape and small size and unlike other types of alopecia no presents signs of redness or swelling.
Alopecia areata is a common autoimmune disease of hair, and attacks both men and women at any age. Until today no effective treatments were known and generally people suffering from the disease that sometimes attacks parts of the body and beard are subject to anxiety disorders, stress and psychological and emotional suffering.
So far it was unknown why the base of the hair follicle died, until Dr. Christiano discovered some few years ago a clue to the genetic cell responsible of future alopecia areata after seeing more than a thousand patients with the disease.
But after the discovery of Dr. Raphael Clynes and his team, today a hope is opened for these patients who suffer from the disease.
Nature Medicine published some time ago the results of a study conducted by researchers at Columbia University Medical Center (CUMC) who have identified a particular type of cells responsible for the death or destruction of hair follicles in alopecia areata. Based on this discovery a new drug has been launched; it has been approved by the U S Food and Drug Administration, better known as FDA.
The magazine mentions that the initial results are encouraging and three patients with mild to severe alopecia areata regained their full hair just 5 months.
Dr. Raphael Clynes Director of the research was optimistic about these encouraging results and said that if the medicine shown safe and effective, it will help thousands of patients suffering from this disease.
The ruxolitinib and tofacitinib drugs approved by the FDA previously were tested in mice and initial experiments successfully blocked cells attacking the hair follicles.
The ruxolitinib was then applied to a small group of human patients with alopecia areata and 3 of the first cases the drug completely restored the lost hair over a period of 5 months.
Dr. Clynes said that ruxolitinib that is used to treat blood disorders could also serve to treat alopecia areata if more sustained and profound studies confirms its inhibiting and locking capacity of cells responsible for the destruction of follicles in the case of alopecia areata.
NOTE: Luis Quiroz Ravines is a Peruvian journalist specializing in Natural Health, author of an effective treatment to stop hair loss naturally. Learn MORE at: http://hairlossnaturalsolution.com/